A. Kerrigan

Three months of rifapentine and isoniazid for latent tuberculosis infection.

J. Hackman, R. Chaisson, M. Conde, 2011, The New England journal of medicine.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production

I. Noth, G. Bernard, G. Ayers, 2018, Science Translational Medicine.

Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis

G. Bernard, G. Ayers, W. Drake, 2020, Chest.

Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

T. Sterling, N. Shang, W. M. Mac Kenzie, 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.

T. Sterling, N. Shang, S. Goldberg, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen

S. Goldberg, J. Saukkonen, Emily J. Hecker, 2020, Clinical trials.

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure

D. Alland, P. Nahid, C. Heilig, 2016, Journal of Clinical Microbiology.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

J. Hackman, R. Chaisson, M. Conde, 2011, The New England journal of medicine.